Your browser is no longer supported. Please, upgrade your browser.
Gracell Biotechnologies Inc.
Index- P/E- EPS (ttm)-0.65 Insider Own- Shs Outstand67.35M Perf Week-5.58%
Market Cap774.52M Forward P/E- EPS next Y-1.70 Insider Trans- Shs Float2.20M Perf Month-19.69%
Income-42.50M PEG- EPS next Q-0.21 Inst Own6.30% Short Float17.91% Perf Quarter-62.38%
Sales- P/S- EPS this Y-36.70% Inst Trans- Short Ratio4.66 Perf Half Y-
Book/sh- P/B- EPS next Y-49.10% ROA- Target Price- Perf Year-
Cash/sh1.78 P/C6.47 EPS next 5Y- ROE- 52W Range10.52 - 33.70 Perf YTD-54.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-65.88% Beta-
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin- 52W Low9.32% ATR1.07
Employees160 Current Ratio8.70 Sales Q/Q- Oper. Margin- RSI (14)30.34 Volatility8.67% 8.17%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.24 Prev Close11.50
ShortableYes LT Debt/Eq- EarningsMar 09 AMC Payout- Avg Volume84.57K Price11.50
Recom1.50 SMA20-9.37% SMA50-33.11% SMA200-43.40% Volume20,591 Change0.00%
Feb-03-21Initiated Citigroup Buy $35
Feb-02-21Initiated Wells Fargo Overweight $33
Feb-02-21Initiated Piper Sandler Overweight $40
Feb-02-21Initiated Jefferies Buy $30
Apr-30-21 05:32PM  
Apr-23-21 06:00PM  
Apr-10-21 09:33AM  
Apr-08-21 05:53AM  
Apr-05-21 08:00AM  
Mar-31-21 08:45AM  
Mar-17-21 08:00AM  
Mar-10-21 05:15AM  
Mar-09-21 04:01PM  
Jan-29-21 08:30PM  
Jan-19-21 06:30AM  
Jan-15-21 08:00AM  
Jan-13-21 08:00AM  
Jan-08-21 01:55AM  
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.